Publisher
Kluwer Academic Publishers
Reference107 articles.
1. Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S: Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 14: 535–541, 1999
2. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S: Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39: 123–129, 1999
3. McCabe NP, Angwafo FF III, Zaher A, Selman SH, Kouinche A, Jankun J: Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol Rep 7: 879–882, 2000
4. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9, 1990
5. Ploug M, Kjalke M, Ronne E, Weidle U, Hoyer-Hansen G, Dano K: Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J Biol Chem 268: 17539–17546, 1993